IB
$207.74
last close 2026-10-23
IBBETF / FundiShares Biotechnology ETF
Verdicts genuinely change. Free email alert the moment IBB's does — no target price to set, unlike "Alert" above.
Whether this fund clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Sharia status
NOT COMPLIANT
Screened by look-through to its filed holdings — 72% of portfolio weight covered
Fund look-through
iShares Biotechnology ETF ETF · iShares Trust
252 holdings · as of 2026-06-30 (3.8 months ago) The fund may have traded since. SEC Form N-PORT is filed quarterly and lags the period it covers, so these are the most recent holdings on file, not the fund’s holdings today.
This fund holds short positions, so exposure is counted gross — long and short both count as exposure rather than netting off, and the weights below therefore sum to 112% of net assets rather than 100%. Shares of the portfolio are shown as shares of that gross exposure.
NON-COMPLIANT 16.54% of portfolio weight is in non-compliant holdings, over the 5% threshold.
252 holdings, 157 matched (72% of weight). Portfolio as of 2026-06-30, filed 2026-08-25. Source: SEC Form N-PORT.
5.74% of this portfolio’s income is non-permissible — weighted across holdings, computed over 60% of portfolio weight (115 of 252 holdings). The common approach purifies that proportion of income received — dividends — not of the position’s value. We report the ratio; what to do with it is a question for your own scholar.
57.7% compliant 0.0% questionable 14.8% non-compliant 27.5% unscreened
All holdings (252) · showing 1–250
| Holding | Status | Weight | Every methodology, and the debt ratio behind it |
|---|---|---|---|
| BlackRock Funds III | UNSCREENED | 11.66% | no in-house ratios for this holding |
| VRTX Vertex Pharmaceuticals, Inc. | COMPLIANT | 8.08% | AAOIFI1.6% Usmani7.2% Dow Jones Islamic1.7% S&P Shariah1.7% MSCI Islamic7.2% MSCI Islamic M-Series1.7% FTSE Shariah0.0% |
| AMGN Amgen, Inc. | COMPLIANT | 7.83% | AAOIFI24.9% Usmani59.9% Dow Jones Islamic33.6% S&P Shariah35.1% MSCI Islamic59.9% MSCI Islamic M-Series35.1% FTSE Shariah59.9% |
| GILD Gilead Sciences, Inc. | COMPLIANT | 6.84% | AAOIFI14.4% Usmani53.2% Dow Jones Islamic18.6% S&P Shariah21.4% MSCI Islamic53.2% MSCI Islamic M-Series21.4% FTSE Shariah53.2% |
| REGN Regeneron Pharmaceuticals, Inc. | COMPLIANT | 4.91% | AAOIFI2.4% Usmani6.5% Dow Jones Islamic3.0% S&P Shariah2.7% MSCI Islamic4.8% MSCI Islamic M-Series2.7% FTSE Shariah4.8% |
| ARGX Argenx SE | COMPLIANT | 3.76% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| ALNY Alnylam Pharmaceuticals, Inc. | COMPLIANT | 3.12% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| NTRA Natera, Inc. | COMPLIANT | 2.89% | AAOIFI0.5% Usmani9.0% Dow Jones Islamic0.9% S&P Shariah1.2% MSCI Islamic9.0% MSCI Islamic M-Series1.2% FTSE Shariah3.0% |
| Revolution Medicines, Inc. | UNSCREENED | 2.78% | no in-house ratios for this holding |
| BIIB Biogen, Inc. | COMPLIANT | 2.47% | AAOIFI21.2% Usmani22.5% Dow Jones Islamic27.5% S&P Shariah24.3% MSCI Islamic22.5% MSCI Islamic M-Series24.3% FTSE Shariah21.3% |
| ILMN Illumina, Inc. | COMPLIANT | 2.07% | AAOIFI1.6% Usmani8.1% Dow Jones Islamic2.7% S&P Shariah2.7% MSCI Islamic8.1% MSCI Islamic M-Series2.7% FTSE Shariah0.0% |
| MRNA Moderna, Inc. | NON_COMPLIANT | 1.98% | AAOIFI2.2% Usmani11.7% Dow Jones Islamic7.4% S&P Shariah5.1% MSCI Islamic11.4% MSCI Islamic M-Series5.1% FTSE Shariah5.4% |
| Insmed, Inc. | UNSCREENED | 1.78% | no in-house ratios for this holding |
| ONC BeOne Medicines Ltd. | COMPLIANT | 1.77% | AAOIFI2.8% Usmani12.5% Dow Jones Islamic0.3% S&P Shariah0.3% MSCI Islamic12.5% MSCI Islamic M-Series0.3% FTSE Shariah11.7% |
| INCY Incyte Corp. | COMPLIANT | 1.75% | AAOIFI0.1% Usmani0.7% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.3% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| UTHR United Therapeutics Corp. | NON_COMPLIANT | 1.73% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| Roivant Sciences Ltd. | UNSCREENED | 1.43% | no in-house ratios for this holding |
| NBIX Neurocrine Biosciences, Inc. | COMPLIANT | 1.30% | AAOIFI2.9% Usmani8.6% Dow Jones Islamic3.4% S&P Shariah3.5% MSCI Islamic8.6% MSCI Islamic M-Series3.5% FTSE Shariah0.0% |
| ASND Ascendis Pharma A/S | COMPLIANT | 1.29% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| GMAB.CO Genmab A/S | COMPLIANT | 1.12% | AAOIFIpass Usmanifail Dow Jones Islamicfail S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| EXEL Exelixis, Inc. | COMPLIANT | 1.03% | AAOIFI1.2% Usmani6.7% Dow Jones Islamic1.5% S&P Shariah1.7% MSCI Islamic6.7% MSCI Islamic M-Series1.7% FTSE Shariah0.0% |
| IONS Ionis Pharmaceuticals, Inc. | NON_COMPLIANT | 1.00% | AAOIFI21.0% Usmani67.5% Dow Jones Islamic23.0% S&P Shariah25.1% MSCI Islamic67.5% MSCI Islamic M-Series25.1% FTSE Shariah58.8% |
| BBIO Bridgebio Pharma, Inc. | COMPLIANT | 0.98% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| MEDP Medpace Holdings, Inc. | COMPLIANT | 0.95% | AAOIFIpass Usmani— Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariah— |
| MDGL Madrigal Pharmaceuticals, Inc. | COMPLIANT | 0.91% | AAOIFI2.8% Usmani27.9% Dow Jones Islamic3.8% S&P Shariah4.6% MSCI Islamic27.9% MSCI Islamic M-Series4.6% FTSE Shariah27.4% |
| TECH Bio-Techne Corp. | COMPLIANT | 0.86% | AAOIFI2.5% Usmani11.2% Dow Jones Islamic3.0% S&P Shariah2.9% MSCI Islamic11.2% MSCI Islamic M-Series2.9% FTSE Shariah7.7% |
| BMRN BioMarin Pharmaceutical, Inc. | NON_COMPLIANT | 0.85% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| CRL Charles River Laboratories International, Inc. | COMPLIANT | 0.84% | AAOIFI21.2% Usmani40.3% Dow Jones Islamic33.1% S&P Shariah30.9% MSCI Islamic40.3% MSCI Islamic M-Series30.9% FTSE Shariah34.9% |
| ARWR Arrowhead Pharmaceuticals, Inc. | COMPLIANT | 0.84% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| AXSM Axsome Therapeutics, Inc. | COMPLIANT | 0.82% | AAOIFI1.9% Usmani29.5% Dow Jones Islamic2.9% S&P Shariah3.5% MSCI Islamic27.6% MSCI Islamic M-Series3.5% FTSE Shariah24.7% |
| CYTK Cytokinetics, Inc. | NON_COMPLIANT | 0.79% | AAOIFI3.9% Usmani20.7% Dow Jones Islamic5.9% S&P Shariah6.2% MSCI Islamic20.7% MSCI Islamic M-Series6.2% FTSE Shariah14.3% |
| KRYS Krystal Biotech, Inc. | NON_COMPLIANT | 0.75% | AAOIFI0.1% Usmani0.6% Dow Jones Islamic0.1% S&P Shariah0.2% MSCI Islamic0.6% MSCI Islamic M-Series0.2% FTSE Shariah0.0% |
| HALO Halozyme Therapeutics, Inc. | COMPLIANT | 0.72% | AAOIFI17.2% Usmani83.3% Dow Jones Islamic27.4% S&P Shariah30.4% MSCI Islamic83.3% MSCI Islamic M-Series30.4% FTSE Shariah83.3% |
| Praxis Precision Medicines, Inc. | UNSCREENED | 0.68% | no in-house ratios for this holding |
| Abivax SA | UNSCREENED | 0.67% | no in-house ratios for this holding |
| ALKS Alkermes plc | COMPLIANT | 0.67% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| 22UA.DE BioNTech SE | NON_COMPLIANT | 0.66% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| Vaxcyte, Inc. | UNSCREENED | 0.64% | no in-house ratios for this holding |
| KYMR Kymera Therapeutics, Inc. | NON_COMPLIANT | 0.64% | AAOIFI0.8% Usmani4.8% Dow Jones Islamic1.7% S&P Shariah2.1% MSCI Islamic4.6% MSCI Islamic M-Series2.1% FTSE Shariah0.0% |
| Apogee Therapeutics, Inc. | UNSCREENED | 0.59% | no in-house ratios for this holding |
| PTGX Protagonist Therapeutics, Inc. | NON_COMPLIANT | 0.58% | AAOIFI0.1% Usmani1.0% Dow Jones Islamic0.2% S&P Shariah0.3% MSCI Islamic1.0% MSCI Islamic M-Series0.3% FTSE Shariah0.0% |
| RYTM Rhythm Pharmaceuticals, Inc. | NON_COMPLIANT | 0.57% | AAOIFI1.8% Usmani25.1% Dow Jones Islamic2.0% S&P Shariah2.4% MSCI Islamic25.1% MSCI Islamic M-Series2.4% FTSE Shariah24.3% |
| RGEN Repligen Corp. | COMPLIANT | 0.57% | AAOIFI7.3% Usmani23.4% Dow Jones Islamic8.8% S&P Shariah8.4% MSCI Islamic23.4% MSCI Islamic M-Series8.4% FTSE Shariah18.7% |
| Spyre Therapeutics, Inc. | UNSCREENED | 0.54% | no in-house ratios for this holding |
| BRKR Bruker Corp. | COMPLIANT | 0.52% | AAOIFI18.9% Usmani30.1% Dow Jones Islamic25.7% S&P Shariah22.6% MSCI Islamic30.1% MSCI Islamic M-Series22.6% FTSE Shariah30.1% |
| PTCT PTC Therapeutics, Inc. | NON_COMPLIANT | 0.51% | AAOIFI11.9% Usmani21.4% Dow Jones Islamic16.9% S&P Shariah20.0% MSCI Islamic21.2% MSCI Islamic M-Series20.0% FTSE Shariah18.2% |
| Nuvalent, Inc. | UNSCREENED | 0.50% | no in-house ratios for this holding |
| TWST Twist Bioscience Corp. | COMPLIANT | 0.48% | AAOIFI1.1% Usmani13.9% Dow Jones Islamic3.2% S&P Shariah3.5% MSCI Islamic13.9% MSCI Islamic M-Series3.5% FTSE Shariah0.0% |
| TEM Tempus AI, Inc. | COMPLIANT | 0.48% | AAOIFI0.7% Usmani3.5% Dow Jones Islamic0.8% S&P Shariahpass MSCI Islamic3.5% MSCI Islamic M-Seriespass FTSE Shariah0.0% |
| MIRM Mirum Pharmaceuticals, Inc. | COMPLIANT | 0.45% | AAOIFI11.6% Usmani73.0% Dow Jones Islamic20.3% S&P Shariah25.7% MSCI Islamic73.0% MSCI Islamic M-Series25.7% FTSE Shariah71.8% |
| Cogent Biosciences, Inc. | UNSCREENED | 0.44% | no in-house ratios for this holding |
| Xenon Pharmaceuticals, Inc. | UNSCREENED | 0.43% | no in-house ratios for this holding |
| Scholar Rock Holding Corp. | UNSCREENED | 0.41% | no in-house ratios for this holding |
| TVTX Travere Therapeutics, Inc. | COMPLIANT | 0.40% | AAOIFI10.0% Usmani77.2% Dow Jones Islamic24.4% S&P Shariah32.6% MSCI Islamic77.2% MSCI Islamic M-Series32.6% FTSE Shariah75.4% |
| Definium Therapeutics, Inc. | UNSCREENED | 0.38% | no in-house ratios for this holding |
| CRSP CRISPR Therapeutics AG | NON_COMPLIANT | 0.38% | AAOIFI15.5% Usmani29.6% Dow Jones Islamic17.0% S&P Shariah16.8% MSCI Islamic29.6% MSCI Islamic M-Series16.8% FTSE Shariah22.1% |
| BlackRock Funds III | UNSCREENED | 0.38% | no in-house ratios for this holding |
| Oruka Therapeutics, Inc. | UNSCREENED | 0.38% | no in-house ratios for this holding |
| VCYT Veracyte, Inc. | COMPLIANT | 0.36% | AAOIFI1.1% Usmani2.7% Dow Jones Islamic1.4% S&P Shariah1.6% MSCI Islamic2.7% MSCI Islamic M-Series1.6% FTSE Shariah0.0% |
| TXG 10X Genomics, Inc. | COMPLIANT | 0.34% | AAOIFI1.0% Usmani7.6% Dow Jones Islamic3.2% S&P Shariah2.5% MSCI Islamic7.6% MSCI Islamic M-Series2.5% FTSE Shariah0.0% |
| LEGN Legend Biotech Corp. | COMPLIANT | 0.33% | AAOIFI8.8% Usmani18.4% Dow Jones Islamic2.9% S&P Shariah2.3% MSCI Islamic18.4% MSCI Islamic M-Series2.3% FTSE Shariah18.4% |
| ACAD ACADIA Pharmaceuticals, Inc. | COMPLIANT | 0.33% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| CG oncology, Inc. | UNSCREENED | 0.32% | no in-house ratios for this holding |
| Denali Therapeutics, Inc. | UNSCREENED | 0.30% | no in-house ratios for this holding |
| Crinetics Pharmaceuticals, Inc. | UNSCREENED | 0.29% | no in-house ratios for this holding |
| Erasca, Inc. | UNSCREENED | 0.27% | no in-house ratios for this holding |
| TNGX Tango Therapeutics, Inc. | NON_COMPLIANT | 0.26% | AAOIFI0.7% Usmani3.0% Dow Jones Islamic1.9% S&P Shariah2.3% MSCI Islamic3.0% MSCI Islamic M-Series2.3% FTSE Shariah0.0% |
| ADPT Adaptive Biotechnologies Corp. | COMPLIANT | 0.26% | AAOIFI2.0% Usmani11.8% Dow Jones Islamic3.9% S&P Shariah5.1% MSCI Islamic11.8% MSCI Islamic M-Series5.1% FTSE Shariah0.0% |
| ImmunityBio, Inc. | UNSCREENED | 0.26% | no in-house ratios for this holding |
| BEAM Beam Therapeutics, Inc. | NON_COMPLIANT | 0.25% | AAOIFI8.2% Usmani17.8% Dow Jones Islamic10.4% S&P Shariah10.7% MSCI Islamic17.8% MSCI Islamic M-Series10.7% FTSE Shariah7.2% |
| Edgewise Therapeutics, Inc. | UNSCREENED | 0.25% | no in-house ratios for this holding |
| GPCR Structure Therapeutics, Inc. | NON_COMPLIANT | 0.24% | AAOIFI0.2% Usmani0.4% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.4% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| Immunovant, Inc. | UNSCREENED | 0.24% | no in-house ratios for this holding |
| IDYA Ideaya Biosciences, Inc. | NON_COMPLIANT | 0.24% | AAOIFI0.8% Usmani2.2% Dow Jones Islamic1.2% S&P Shariah1.1% MSCI Islamic2.2% MSCI Islamic M-Series1.1% FTSE Shariah0.0% |
| RARE Ultragenyx Pharmaceutical, Inc. | NON_COMPLIANT | 0.23% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| Dyne Therapeutics, Inc. | UNSCREENED | 0.23% | no in-house ratios for this holding |
| ARQT Arcutis Biotherapeutics, Inc. | COMPLIANT | 0.23% | AAOIFI3.8% Usmani23.4% Dow Jones Islamic5.0% S&P Shariah6.5% MSCI Islamic23.4% MSCI Islamic M-Series6.5% FTSE Shariah22.3% |
| Newamsterdam Pharma Co. NV | UNSCREENED | 0.21% | no in-house ratios for this holding |
| GRAL GRAIL, Inc. | NON_COMPLIANT | 0.21% | AAOIFI2.5% Usmani3.2% Dow Jones Islamic4.7% S&P Shariahfail MSCI Islamic3.2% MSCI Islamic M-Seriesfail FTSE Shariah0.0% |
| Relay Therapeutics, Inc. | UNSCREENED | 0.21% | no in-house ratios for this holding |
| uniQure NV | UNSCREENED | 0.20% | no in-house ratios for this holding |
| RCUS Arcus Biosciences, Inc. | COMPLIANT | 0.20% | AAOIFI4.0% Usmani12.3% Dow Jones Islamic5.6% S&P Shariah6.2% MSCI Islamic12.3% MSCI Islamic M-Series6.2% FTSE Shariah10.9% |
| TARS Tarsus Pharmaceuticals, Inc. | COMPLIANT | 0.20% | AAOIFI2.3% Usmani14.5% Dow Jones Islamic3.8% S&P Shariah4.7% MSCI Islamic14.5% MSCI Islamic M-Series4.7% FTSE Shariah11.9% |
| Vera Therapeutics, Inc. | UNSCREENED | 0.20% | no in-house ratios for this holding |
| Enliven Therapeutics, Inc. | UNSCREENED | 0.19% | no in-house ratios for this holding |
| NRIX Nurix Therapeutics, Inc. | NON_COMPLIANT | 0.19% | AAOIFI2.1% Usmani10.9% Dow Jones Islamic4.1% S&P Shariah5.0% MSCI Islamic10.9% MSCI Islamic M-Series5.0% FTSE Shariah0.0% |
| Alumis, Inc. | UNSCREENED | 0.18% | no in-house ratios for this holding |
| Kodiak Sciences, Inc. | UNSCREENED | 0.18% | no in-house ratios for this holding |
| VCEL Vericel Corp. | COMPLIANT | 0.18% | AAOIFI4.0% Usmani18.5% Dow Jones Islamic4.4% S&P Shariah4.4% MSCI Islamic18.4% MSCI Islamic M-Series4.4% FTSE Shariah0.0% |
| NTLA Intellia Therapeutics, Inc. | NON_COMPLIANT | 0.17% | AAOIFI4.1% Usmani8.6% Dow Jones Islamic5.1% S&P Shariah4.1% MSCI Islamic8.6% MSCI Islamic M-Series4.1% FTSE Shariah0.0% |
| CAI Caris Life Sciences, Inc. | COMPLIANT | 0.17% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| BioCryst Pharmaceuticals, Inc. | UNSCREENED | 0.17% | no in-house ratios for this holding |
| AGIO Agios Pharmaceuticals, Inc. | NON_COMPLIANT | 0.16% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| Disc Medicine, Inc. | UNSCREENED | 0.16% | no in-house ratios for this holding |
| Summit Therapeutics, Inc. | UNSCREENED | 0.15% | no in-house ratios for this holding |
| AUPH Aurinia Pharmaceuticals, Inc. | COMPLIANT | 0.15% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| ADMA ADMA Biologics, Inc. | COMPLIANT | 0.15% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahpass |
| Biohaven Ltd. | UNSCREENED | 0.15% | no in-house ratios for this holding |
| ZYME Zymeworks, Inc. | NON_COMPLIANT | 0.14% | AAOIFI1.0% Usmani4.0% Dow Jones Islamic1.2% S&P Shariah1.5% MSCI Islamic4.0% MSCI Islamic M-Series1.5% FTSE Shariah0.0% |
| AnaptysBio, Inc. | UNSCREENED | 0.14% | no in-house ratios for this holding |
| ABCL AbCellera Biologics, Inc. | NON_COMPLIANT | 0.14% | AAOIFI3.8% Usmani10.4% Dow Jones Islamic11.0% S&P Shariah11.0% MSCI Islamic10.4% MSCI Islamic M-Series11.0% FTSE Shariah0.0% |
| Sarepta Therapeutics, Inc. | UNSCREENED | 0.14% | no in-house ratios for this holding |
| Syndax Pharmaceuticals, Inc. | UNSCREENED | 0.14% | no in-house ratios for this holding |
| Trevi Therapeutics, Inc. | UNSCREENED | 0.14% | no in-house ratios for this holding |
| RXRX Recursion Pharmaceuticals, Inc. | NON_COMPLIANT | 0.13% | AAOIFI3.4% Usmani5.5% Dow Jones Islamic7.3% S&P Shariah6.1% MSCI Islamic5.5% MSCI Islamic M-Series6.1% FTSE Shariah1.2% |
| 9688.HK Zai Lab Ltd. | NON_COMPLIANT | 0.13% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| Amylyx Pharmaceuticals, Inc. | UNSCREENED | 0.13% | no in-house ratios for this holding |
| Mineralys Therapeutics, Inc. | UNSCREENED | 0.13% | no in-house ratios for this holding |
| FTRE Fortrea Holdings, Inc. | NON_COMPLIANT | 0.13% | AAOIFI66.4% Usmani41.2% Dow Jones Islamic92.8% S&P Shariah65.5% MSCI Islamic41.2% MSCI Islamic M-Series65.5% FTSE Shariah38.8% |
| TSHA Taysha Gene Therapies, Inc. | NON_COMPLIANT | 0.13% | AAOIFI3.1% Usmani12.1% Dow Jones Islamic5.9% S&P Shariah7.4% MSCI Islamic12.0% MSCI Islamic M-Series7.4% FTSE Shariah10.5% |
| MBX Biosciences, Inc. | UNSCREENED | 0.13% | no in-house ratios for this holding |
| STOK Stoke Therapeutics, Inc. | NON_COMPLIANT | 0.13% | AAOIFI0.1% Usmani0.7% Dow Jones Islamic0.2% S&P Shariah0.3% MSCI Islamic0.7% MSCI Islamic M-Series0.3% FTSE Shariah0.0% |
| IOVA Iovance Biotherapeutics, Inc. | COMPLIANT | 0.13% | AAOIFI1.2% Usmani5.0% Dow Jones Islamic2.9% S&P Shariah2.4% MSCI Islamic5.0% MSCI Islamic M-Series2.4% FTSE Shariah0.0% |
| NVCR Novocure Ltd. | NON_COMPLIANT | 0.12% | AAOIFI13.9% Usmani29.2% Dow Jones Islamic12.6% S&P Shariah12.9% MSCI Islamic29.2% MSCI Islamic M-Series12.9% FTSE Shariah24.5% |
| GRF.MC Grifols SA | NON_COMPLIANT | 0.12% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| ATAI AtaiBeckley, Inc. | NON_COMPLIANT | 0.12% | AAOIFI0.9% Usmani9.4% Dow Jones Islamic2.0% S&P Shariah2.5% MSCI Islamic9.4% MSCI Islamic M-Series2.5% FTSE Shariah8.7% |
| ABSI Absci Corp. | COMPLIANT | 0.12% | AAOIFI— Usmanifail Dow Jones Islamicfail S&P Shariah— MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| Compass Pathways plc | UNSCREENED | 0.12% | no in-house ratios for this holding |
| URGN UroGen Pharma Ltd. | NON_COMPLIANT | 0.12% | AAOIFI8.9% Usmani77.6% Dow Jones Islamic21.2% S&P Shariah25.0% MSCI Islamic75.9% MSCI Islamic M-Series25.0% FTSE Shariah74.7% |
| NVAX Novavax, Inc. | NON_COMPLIANT | 0.12% | AAOIFI17.3% Usmani31.1% Dow Jones Islamic21.2% S&P Shariah22.9% MSCI Islamic30.5% MSCI Islamic M-Series22.9% FTSE Shariah30.5% |
| TYRA Tyra Biosciences, Inc. | COMPLIANT | 0.11% | AAOIFI0.3% Usmani1.5% Dow Jones Islamic0.5% S&P Shariah0.6% MSCI Islamic1.5% MSCI Islamic M-Series0.6% FTSE Shariah0.0% |
| GLUE Monte Rosa Therapeutics, Inc. | NON_COMPLIANT | 0.11% | AAOIFI4.3% Usmani5.5% Dow Jones Islamic4.5% S&P Shariah5.9% MSCI Islamic5.5% MSCI Islamic M-Series5.9% FTSE Shariah0.0% |
| NUVB Nuvation Bio, Inc. | NON_COMPLIANT | 0.11% | AAOIFI10.5% Usmani33.9% Dow Jones Islamic18.7% S&P Shariah23.6% MSCI Islamic33.9% MSCI Islamic M-Series23.6% FTSE Shariah33.4% |
| VIR Vir Biotechnology, Inc. | NON_COMPLIANT | 0.11% | AAOIFI6.1% Usmani7.7% Dow Jones Islamic8.6% S&P Shariah8.1% MSCI Islamic7.7% MSCI Islamic M-Series8.1% FTSE Shariah0.0% |
| IMCR Immunocore Holdings plc | NON_COMPLIANT | 0.10% | AAOIFI24.8% Usmani42.8% Dow Jones Islamic29.4% S&P Shariah24.5% MSCI Islamic42.8% MSCI Islamic M-Series24.5% FTSE Shariah39.2% |
| CDNA CareDx, Inc. | COMPLIANT | 0.10% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| GH Research plc | UNSCREENED | 0.10% | no in-house ratios for this holding |
| MNKD MannKind Corp. | NON_COMPLIANT | 0.10% | AAOIFI34.1% Usmani45.2% Dow Jones Islamic23.3% S&P Shariah24.3% MSCI Islamic45.2% MSCI Islamic M-Series24.3% FTSE Shariah43.6% |
| LKFT.AS Lakefront Biotherapeutics NV | NON_COMPLIANT | 0.10% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| Rapport Therapeutics, Inc. | UNSCREENED | 0.09% | no in-house ratios for this holding |
| Sionna Therapeutics, Inc. | UNSCREENED | 0.09% | no in-house ratios for this holding |
| ArriVent Biopharma, Inc. | UNSCREENED | 0.09% | no in-house ratios for this holding |
| Xencor, Inc. | UNSCREENED | 0.09% | no in-house ratios for this holding |
| Bicara Therapeutics, Inc. | UNSCREENED | 0.09% | no in-house ratios for this holding |
| Inhibrx Biosciences, Inc. | UNSCREENED | 0.08% | no in-house ratios for this holding |
| MAZE Maze Therapeutics, Inc. | COMPLIANT | 0.08% | AAOIFI4.2% Usmani11.4% Dow Jones Islamicfail S&P Shariahfail MSCI Islamic11.4% MSCI Islamic M-Seriesfail FTSE Shariah7.3% |
| Pharvaris NV | UNSCREENED | 0.08% | no in-house ratios for this holding |
| WVE WaVe Life Sciences Ltd. | NON_COMPLIANT | 0.08% | AAOIFI3.9% Usmani7.8% Dow Jones Islamic2.9% S&P Shariah3.6% MSCI Islamic7.8% MSCI Islamic M-Series3.6% FTSE Shariah0.0% |
| STVN Stevanato Group SpA | COMPLIANT | 0.07% | AAOIFI8.2% Usmani17.9% Dow Jones Islamic8.6% S&P Shariah8.0% MSCI Islamic17.9% MSCI Islamic M-Series8.0% FTSE Shariah17.9% |
| MESO Mesoblast Ltd. | COMPLIANT | 0.07% | AAOIFI4.7% Usmani16.2% Dow Jones Islamic0.7% S&P Shariah1.0% MSCI Islamic16.2% MSCI Islamic M-Series1.0% FTSE Shariah16.2% |
| MGTX MeiraGTx Holdings plc | COMPLIANT | 0.07% | AAOIFI0.9% Usmani3.1% Dow Jones Islamic1.9% S&P Shariah2.2% MSCI Islamic3.1% MSCI Islamic M-Series2.2% FTSE Shariah0.0% |
| CRVS Corvus Pharmaceuticals, Inc. | COMPLIANT | 0.07% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| Kura Oncology, Inc. | UNSCREENED | 0.07% | no in-house ratios for this holding |
| SEPN Septerna, Inc. | NON_COMPLIANT | 0.07% | AAOIFI1.3% Usmani4.0% Dow Jones Islamic2.4% S&P Shariahfail MSCI Islamic4.0% MSCI Islamic M-Seriesfail FTSE Shariah0.0% |
| PGEN Precigen, Inc. | NON_COMPLIANT | 0.07% | AAOIFI3.9% Usmani57.7% Dow Jones Islamic9.9% S&P Shariah12.7% MSCI Islamic57.7% MSCI Islamic M-Series12.7% FTSE Shariah55.1% |
| OLMA Olema Pharmaceuticals, Inc. | NON_COMPLIANT | 0.07% | AAOIFI0.1% Usmani0.1% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.1% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| JANX Janux Therapeutics, Inc. | NON_COMPLIANT | 0.07% | AAOIFI1.7% Usmani2.1% Dow Jones Islamic1.4% S&P Shariah1.4% MSCI Islamic2.1% MSCI Islamic M-Series1.4% FTSE Shariah0.0% |
| Replimune Group, Inc. | UNSCREENED | 0.07% | no in-house ratios for this holding |
| Zevra Therapeutics, Inc. | UNSCREENED | 0.06% | no in-house ratios for this holding |
| PSNL Personalis, Inc. | NON_COMPLIANT | 0.06% | AAOIFI2.0% Usmani11.9% Dow Jones Islamic5.7% S&P Shariah8.0% MSCI Islamic11.9% MSCI Islamic M-Series8.0% FTSE Shariah0.0% |
| Alto Neuroscience, Inc. | UNSCREENED | 0.06% | no in-house ratios for this holding |
| Cullinan Therapeutics, Inc. | UNSCREENED | 0.06% | no in-house ratios for this holding |
| Theravance Biopharma, Inc. | UNSCREENED | 0.06% | no in-house ratios for this holding |
| ANNX Annexon, Inc. | COMPLIANT | 0.06% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| ZBIO Zenas Biopharma, Inc. | NON_COMPLIANT | 0.06% | AAOIFI3.9% Usmani11.3% Dow Jones Islamic8.0% S&P Shariah— MSCI Islamic11.3% MSCI Islamic M-Series— FTSE Shariah11.2% |
| Geron Corp. | UNSCREENED | 0.06% | no in-house ratios for this holding |
| Solid Biosciences, Inc. | UNSCREENED | 0.06% | no in-house ratios for this holding |
| BIOA BioAge Labs, Inc. | NON_COMPLIANT | 0.06% | AAOIFI0.6% Usmani0.7% Dow Jones Islamic0.6% S&P Shariah— MSCI Islamic0.7% MSCI Islamic M-Series— FTSE Shariah0.0% |
| ABUS Arbutus Biopharma Corp. | NON_COMPLIANT | 0.06% | AAOIFI0.1% Usmani0.2% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.2% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| CSTL Castle Biosciences, Inc. | NON_COMPLIANT | 0.05% | AAOIFI3.3% Usmani6.5% Dow Jones Islamic4.7% S&P Shariah5.1% MSCI Islamic6.5% MSCI Islamic M-Series5.1% FTSE Shariah1.8% |
| RIGL Rigel Pharmaceuticals, Inc. | COMPLIANT | 0.05% | AAOIFI5.0% Usmani8.8% Dow Jones Islamic9.0% S&P Shariah11.3% MSCI Islamic8.8% MSCI Islamic M-Series11.3% FTSE Shariah8.6% |
| IRWD Ironwood Pharmaceuticals, Inc. | NON_COMPLIANT | 0.05% | AAOIFI30.0% Usmani74.1% Dow Jones Islamic45.1% S&P Shariah27.1% MSCI Islamic74.1% MSCI Islamic M-Series27.1% FTSE Shariah70.0% |
| ORIC ORIC Pharmaceuticals, Inc. | COMPLIANT | 0.05% | AAOIFI0.3% Usmani0.8% Dow Jones Islamic0.4% S&P Shariah0.4% MSCI Islamic0.8% MSCI Islamic M-Series0.4% FTSE Shariah0.0% |
| SVRA Savara, Inc. | NON_COMPLIANT | 0.05% | AAOIFI2.7% Usmani15.7% Dow Jones Islamic3.9% S&P Shariah4.2% MSCI Islamic15.7% MSCI Islamic M-Series4.2% FTSE Shariah15.7% |
| MRVI Maravai LifeSciences Holdings, Inc. | NON_COMPLIANT | 0.05% | AAOIFI7.7% Usmani29.3% Dow Jones Islamic13.5% S&P Shariah10.6% MSCI Islamic24.4% MSCI Islamic M-Series10.6% FTSE Shariah24.4% |
| Sana Biotechnology, Inc. | UNSCREENED | 0.05% | no in-house ratios for this holding |
| CTMX CytomX Therapeutics, Inc. | NON_COMPLIANT | 0.05% | AAOIFI0.7% Usmani1.5% Dow Jones Islamic1.3% S&P Shariah1.8% MSCI Islamic1.5% MSCI Islamic M-Series1.8% FTSE Shariah0.0% |
| FDMT 4D Molecular Therapeutics, Inc. | NON_COMPLIANT | 0.05% | AAOIFI4.7% Usmani8.0% Dow Jones Islamic9.8% S&P Shariah6.8% MSCI Islamic8.0% MSCI Islamic M-Series6.8% FTSE Shariah4.0% |
| PHAT Phathom Pharmaceuticals, Inc. | NON_COMPLIANT | 0.05% | AAOIFI55.2% Usmani123.6% Dow Jones Islamic53.0% S&P Shariah57.8% MSCI Islamic123.6% MSCI Islamic M-Series57.8% FTSE Shariah122.8% |
| Candel Therapeutics, Inc. | UNSCREENED | 0.05% | no in-house ratios for this holding |
| ACRS Aclaris Therapeutics, Inc. | NON_COMPLIANT | 0.05% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| RGNX REGENXBIO, Inc. | NON_COMPLIANT | 0.04% | AAOIFI11.7% Usmani17.8% Dow Jones Islamic14.0% S&P Shariah12.0% MSCI Islamic17.8% MSCI Islamic M-Series12.0% FTSE Shariah0.0% |
| OPK OPKO Health, Inc. | NON_COMPLIANT | 0.04% | AAOIFI4.2% Usmani2.8% Dow Jones Islamic4.6% S&P Shariah4.7% MSCI Islamic2.6% MSCI Islamic M-Series4.7% FTSE Shariah0.1% |
| Altimmune, Inc. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| Design Therapeutics, Inc. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| Allogene Therapeutics, Inc. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| Cytek Biosciences, Inc. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| MYGN Myriad Genetics, Inc. | NON_COMPLIANT | 0.04% | AAOIFI69.0% Usmani32.9% Dow Jones Islamic25.9% S&P Shariah18.2% MSCI Islamic32.9% MSCI Islamic M-Series18.2% FTSE Shariah18.9% |
| SPRY ARS Pharmaceuticals, Inc. | NON_COMPLIANT | 0.04% | AAOIFI23.3% Usmani38.7% Dow Jones Islamic9.1% S&P Shariah9.8% MSCI Islamic38.7% MSCI Islamic M-Series9.8% FTSE Shariah38.7% |
| DNA Ginkgo Bioworks Holdings, Inc. | NON_COMPLIANT | 0.04% | AAOIFI86.3% Usmani40.8% Dow Jones Islamic70.5% S&P Shariah31.1% MSCI Islamic40.8% MSCI Islamic M-Series31.1% FTSE Shariah0.0% |
| CTNM Contineum Therapeutics, Inc. | NON_COMPLIANT | 0.04% | AAOIFI1.0% Usmani2.6% Dow Jones Islamic2.5% S&P Shariah2.4% MSCI Islamic2.6% MSCI Islamic M-Series2.4% FTSE Shariah0.0% |
| PACB Pacific Biosciences of California, Inc. | NON_COMPLIANT | 0.04% | AAOIFI168.3% Usmani93.9% Dow Jones Islamic143.6% S&P Shariah79.6% MSCI Islamic93.9% MSCI Islamic M-Series79.6% FTSE Shariah85.7% |
| C4 Therapeutics, Inc. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| Aura Biosciences, Inc. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| SGMT Sagimet Biosciences, Inc. | NON_COMPLIANT | 0.04% | AAOIFI0.3% Usmani0.7% Dow Jones Islamic1.0% S&P Shariah1.2% MSCI Islamic0.7% MSCI Islamic M-Series1.2% FTSE Shariah0.0% |
| Arvinas, Inc. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| Cabaletta Bio, Inc. | UNSCREENED | 0.03% | no in-house ratios for this holding |
| PRTA Prothena Corp. plc | NON_COMPLIANT | 0.03% | AAOIFI1.4% Usmani2.3% Dow Jones Islamic1.2% S&P Shariah0.8% MSCI Islamic2.3% MSCI Islamic M-Series0.8% FTSE Shariah0.0% |
| ALVO Alvotech SA | NON_COMPLIANT | 0.03% | AAOIFI61.2% Usmani87.4% Dow Jones Islamic56.2% S&P Shariah50.1% MSCI Islamic87.4% MSCI Islamic M-Series50.1% FTSE Shariah87.4% |
| EBS Emergent BioSolutions, Inc. | NON_COMPLIANT | 0.03% | AAOIFI184.7% Usmani52.7% Dow Jones Islamic132.4% S&P Shariah158.7% MSCI Islamic52.7% MSCI Islamic M-Series158.7% FTSE Shariah52.1% |
| Enanta Pharmaceuticals, Inc. | UNSCREENED | 0.03% | no in-house ratios for this holding |
| NGNE Neurogene, Inc. | NON_COMPLIANT | 0.03% | AAOIFI1.1% Usmani3.4% Dow Jones Islamic2.2% S&P Shariah2.5% MSCI Islamic3.4% MSCI Islamic M-Series2.5% FTSE Shariah0.0% |
| FLGT Fulgent Genetics, Inc. | NON_COMPLIANT | 0.03% | AAOIFI1.4% Usmani0.7% Dow Jones Islamic1.2% S&P Shariah1.1% MSCI Islamic0.7% MSCI Islamic M-Series1.1% FTSE Shariah0.0% |
| RCKT Rocket Pharmaceuticals, Inc. | NON_COMPLIANT | 0.03% | AAOIFI0.8% Usmani5.9% Dow Jones Islamic0.5% S&P Shariah0.3% MSCI Islamic0.8% MSCI Islamic M-Series0.3% FTSE Shariah0.0% |
| PRME Prime Medicine, Inc. | NON_COMPLIANT | 0.03% | AAOIFI16.8% Usmani45.2% Dow Jones Islamic21.9% S&P Shariah18.8% MSCI Islamic45.2% MSCI Islamic M-Series18.8% FTSE Shariah0.0% |
| VNDA Vanda Pharmaceuticals, Inc. | NON_COMPLIANT | 0.03% | AAOIFI6.5% Usmani5.5% Dow Jones Islamic4.9% S&P Shariah5.1% MSCI Islamic3.8% MSCI Islamic M-Series5.1% FTSE Shariah0.0% |
| KYTX Kyverna Therapeutics, Inc. | NON_COMPLIANT | 0.03% | AAOIFI6.4% Usmani15.0% Dow Jones Islamic11.3% S&P Shariah8.6% MSCI Islamic15.0% MSCI Islamic M-Series8.6% FTSE Shariah11.3% |
| BridgeBio Oncology Therapeutics, Inc. | UNSCREENED | 0.03% | no in-house ratios for this holding |
| TECX Tectonic Therapeutic, Inc. | NON_COMPLIANT | 0.03% | AAOIFI0.7% Usmani1.9% Dow Jones Islamic0.9% S&P Shariah1.2% MSCI Islamic1.8% MSCI Islamic M-Series1.2% FTSE Shariah0.0% |
| 6A3A.SG Autolus Therapeutics plc | NON_COMPLIANT | 0.03% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| EDIT Editas Medicine, Inc. | NON_COMPLIANT | 0.02% | AAOIFI14.4% Usmani30.0% Dow Jones Islamic30.8% S&P Shariah20.4% MSCI Islamic30.0% MSCI Islamic M-Series20.4% FTSE Shariah23.5% |
| LAB Standard BioTools, Inc. | NON_COMPLIANT | 0.02% | AAOIFI11.0% Usmani4.5% Dow Jones Islamic5.4% S&P Shariah4.3% MSCI Islamic4.5% MSCI Islamic M-Series4.3% FTSE Shariah0.0% |
| CATX Perspective Therapeutics, Inc. | NON_COMPLIANT | 0.02% | AAOIFI1.1% Usmani1.0% Dow Jones Islamic1.1% S&P Shariah1.0% MSCI Islamic1.0% MSCI Islamic M-Series1.0% FTSE Shariah0.4% |
| SLN Silence Therapeutics plc | NON_COMPLIANT | 0.02% | AAOIFI0.0% Usmani0.1% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.1% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| OABI OmniAb, Inc. | NON_COMPLIANT | 0.02% | AAOIFI3.0% Usmani6.5% Dow Jones Islamic5.9% S&P Shariah4.7% MSCI Islamic6.5% MSCI Islamic M-Series4.7% FTSE Shariah0.0% |
| Atea Pharmaceuticals, Inc. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| Lexeo Therapeutics, Inc. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| Immuneering Corp. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| UPB Upstream Bio, Inc. | NON_COMPLIANT | 0.02% | AAOIFI0.3% Usmani0.3% Dow Jones Islamic0.1% S&P Shariah— MSCI Islamic0.3% MSCI Islamic M-Series— FTSE Shariah0.0% |
| LCTX Lineage Cell Therapeutics, Inc. | NON_COMPLIANT | 0.02% | AAOIFI0.8% Usmani2.2% Dow Jones Islamic0.9% S&P Shariah0.9% MSCI Islamic2.1% MSCI Islamic M-Series0.9% FTSE Shariah0.0% |
| Anavex Life Sciences Corp. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| Fulcrum Therapeutics, Inc. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| KROS Keros Therapeutics, Inc. | NON_COMPLIANT | 0.02% | AAOIFI7.4% Usmani5.5% Dow Jones Islamic3.8% S&P Shariah2.7% MSCI Islamic5.5% MSCI Islamic M-Series2.7% FTSE Shariah0.0% |
| Codexis, Inc. | UNSCREENED | 0.01% | no in-house ratios for this holding |
| Arcturus Therapeutics Holdings, Inc. | UNSCREENED | 0.01% | no in-house ratios for this holding |
| VYGR Voyager Therapeutics, Inc. | NON_COMPLIANT | 0.01% | AAOIFI17.2% Usmani16.5% Dow Jones Islamic13.5% S&P Shariah11.1% MSCI Islamic16.5% MSCI Islamic M-Series11.1% FTSE Shariah0.0% |
| QTRX Quanterix Corp. | NON_COMPLIANT | 0.01% | AAOIFI25.2% Usmani10.4% Dow Jones Islamic10.4% S&P Shariah6.1% MSCI Islamic10.4% MSCI Islamic M-Series6.1% FTSE Shariah0.0% |
| NBP NovaBridge Biosciences | NON_COMPLIANT | 0.01% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariah— MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| Larimar Therapeutics, Inc. | UNSCREENED | 0.01% | no in-house ratios for this holding |
| PYXS Pyxis Oncology, Inc. | NON_COMPLIANT | 0.01% | AAOIFI8.9% Usmani32.5% Dow Jones Islamic13.3% S&P Shariah11.8% MSCI Islamic32.5% MSCI Islamic M-Series11.8% FTSE Shariah0.0% |
| HUMA Humacyte, Inc. | NON_COMPLIANT | 0.01% | AAOIFI21.6% Usmani47.9% Dow Jones Islamic11.0% S&P Shariah9.5% MSCI Islamic26.3% MSCI Islamic M-Series9.5% FTSE Shariah26.3% |
| TRDA Entrada Therapeutics, Inc. | NON_COMPLIANT | 0.01% | AAOIFI17.5% Usmani16.2% Dow Jones Islamic12.3% S&P Shariah11.3% MSCI Islamic16.2% MSCI Islamic M-Series11.3% FTSE Shariah0.0% |
| Caribou Biosciences, Inc. | UNSCREENED | 0.01% | no in-house ratios for this holding |
| TNYA Tenaya Therapeutics, Inc. | NON_COMPLIANT | 0.01% | AAOIFI2.6% Usmani4.2% Dow Jones Islamic2.6% S&P Shariah2.1% MSCI Islamic4.2% MSCI Islamic M-Series2.1% FTSE Shariah0.0% |
| LENZ LENZ Therapeutics, Inc. | NON_COMPLIANT | 0.01% | AAOIFI0.3% Usmani0.2% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.2% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| FHTX Foghorn Therapeutics, Inc. | NON_COMPLIANT | 0.01% | AAOIFI14.8% Usmani21.2% Dow Jones Islamic14.3% S&P Shariah15.2% MSCI Islamic21.2% MSCI Islamic M-Series15.2% FTSE Shariah0.0% |
| Quantum-Si, Inc. | UNSCREENED | 0.01% | no in-house ratios for this holding |
| ACIU AC Immune SA | NON_COMPLIANT | 0.01% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariah— MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| 50BA.SG Bicycle Therapeutics plc | NON_COMPLIANT | 0.01% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| Neumora Therapeutics, Inc. | UNSCREENED | 0.01% | no in-house ratios for this holding |
| PEPG PepGen, Inc. | NON_COMPLIANT | 0.01% | AAOIFI7.5% Usmani11.4% Dow Jones Islamic9.4% S&P Shariah7.4% MSCI Islamic11.4% MSCI Islamic M-Series7.4% FTSE Shariah0.0% |
| LYEL Lyell Immunopharma, Inc. | NON_COMPLIANT | 0.01% | AAOIFI14.1% Usmani15.0% Dow Jones Islamic14.9% S&P Shariah12.4% MSCI Islamic15.0% MSCI Islamic M-Series12.4% FTSE Shariah0.0% |
| ADCT ADC Therapeutics SA | NON_COMPLIANT | 0.01% | AAOIFI76.8% Usmani47.7% Dow Jones Islamic42.6% S&P Shariah46.7% MSCI Islamic47.7% MSCI Islamic M-Series46.7% FTSE Shariah47.4% |
| Cellectis SA | UNSCREENED | 0.01% | no in-house ratios for this holding |
| Black Diamond Therapeutics, Inc. | UNSCREENED | 0.01% | no in-house ratios for this holding |
| AARD Aardvark Therapeutics, Inc. | NON_COMPLIANT | 0.01% | AAOIFIfail Usmanifail Dow Jones Islamic— S&P Shariah— MSCI Islamicfail MSCI Islamic M-Series— FTSE Shariahfail |
| TKNO Alpha Teknova, Inc. | COMPLIANT | 0.00% | AAOIFI7.3% Usmani28.6% Dow Jones Islamic9.7% S&P Shariah12.3% MSCI Islamic28.6% MSCI Islamic M-Series12.3% FTSE Shariah13.8% |
| Jyong Biotech Ltd. | UNSCREENED | 0.00% | no in-house ratios for this holding |
| Akero Therapeutics, Inc. | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| IMM.AX Immutep Ltd. | NON_COMPLIANT | 0.00% | AAOIFI1.6% Usmani1.6% Dow Jones Islamic— S&P Shariah— MSCI Islamic0.8% MSCI Islamic M-Series— FTSE Shariah0.8% |
| GOSS Gossamer Bio, Inc. | NON_COMPLIANT | 0.00% | AAOIFI4.6% Usmani5.1% Dow Jones Islamic1.3% S&P Shariah1.5% MSCI Islamic5.1% MSCI Islamic M-Series1.5% FTSE Shariah0.0% |
| Contra Chinook Therape | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| Arcellx, Inc. | UNSCREENED | 0.00% | no in-house ratios for this holding |
| RNAC Cartesian Therapeutics, Inc. | NON_COMPLIANT | 0.00% | AAOIFI22.8% Usmani20.0% Dow Jones Islamic21.3% S&P Shariah23.4% MSCI Islamic20.0% MSCI Islamic M-Series23.4% FTSE Shariah16.6% |
| Fusion Pharmaceuticals, Inc. | UNSCREENED | 0.00% | no in-house ratios for this holding |
| Cargo Therapeutics, Inc. | UNSCREENED | 0.00% | no in-house ratios for this holding |
| Akouos, Inc. | UNSCREENED | 0.00% | no in-house ratios for this holding |
| Third Harmonic Bio, Inc. | UNSCREENED | 0.00% | no in-house ratios for this holding |
The published standards disagree about this fund by 33 points of portfolio weight — 41.2% of it passes AAOIFI, 8.7% passes MSCI Islamic. Which number is yours depends on which standard you follow.
These bars are the financial-ratio result under each standard — debt, receivables and interest income. They do not screen what the business does, so a holding can pass every ratio here and still be questionable or non-compliant on activity. The blended verdict above accounts for both.
ratios pass on 41.2% ratios fail on 18.2% 52.5% not rated under AAOIFI
ratios pass on 11.6% ratios fail on 46.1% 54.1% not rated under Usmani
ratios pass on 30.5% ratios fail on 28.2% 53.2% not rated under Dow Jones Islamic
ratios pass on 32.6% ratios fail on 25.4% 53.9% not rated under S&P Shariah
ratios pass on 8.7% ratios fail on 58.6% 44.6% not rated under MSCI Islamic
ratios pass on 32.5% ratios fail on 25.7% 53.7% not rated under MSCI Islamic M-Series
ratios pass on 11.6% ratios fail on 46.0% 54.3% not rated under FTSE Shariah
156 of 252 listed holdings carry our own per-methodology verdicts (81% of weight). The rest hold a provider verdict with no methodology breakdown, and are counted as rated by none. Of those, 128 (65% of weight) also carry the underlying debt ratio; the rest show a verdict without the figure behind it.
| Non-compliant holding | Weight |
|---|---|
| MRNA Moderna, Inc. | 1.98% |
| UTHR United Therapeutics Corp. | 1.73% |
| IONS Ionis Pharmaceuticals, Inc. | 1.00% |
| BMRN BioMarin Pharmaceutical, Inc. | 0.85% |
| CYTK Cytokinetics, Inc. | 0.79% |
| KRYS Krystal Biotech, Inc. | 0.75% |
| 22UA.DE BioNTech SE | 0.66% |
| KYMR Kymera Therapeutics, Inc. | 0.64% |
| PTGX Protagonist Therapeutics, Inc. | 0.58% |
| RYTM Rhythm Pharmaceuticals, Inc. | 0.57% |
Methodology breakdown computing — it will appear here on its own.
🕌Open research, not a fatwa — verify with your own scholar.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
Structure3 of 5 timeframes bullish · 73.9% aligned
VWAPPrice below VWAP ($209.04)
VolumeRelative volume 3.8× the 20-day average
Momentum10-day rate of change +0.6%
iShares Biotechnology ETF (IBB) is currently considered not halal (non-compliant), per our own look-through to its filed holdings. See its filed holdings and the weight breakdown below for the reasoning.
Market & analysts
Momentum (10d)
+0.6%
rate of change
SMC grade
F · 32
73.9% aligned
F · 32
SMC grade — 73.9% timeframe alignment
+0.6%
Rate of change (10d)
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for IBB — this runs off the critical path so the page paints first. It will appear here on its own.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Fisher | Fisher Asset Management | $0M | 0.0% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Support & Resistance
S3
200.37
S2
203.58
S1
206.56
PIVOT
209.77
R1
212.75
R2
215.96
R3
218.94
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
7-day expected range
194.74
–
216.24
±5.23% from 205.49, made 2026-09-10 · resolves 2026-09-17
BUY
from 19 indicators
61.9% of our last
5789 forecasts — across every
instrument we forecast, not just this one — landed inside their
stated range, and
49.9% called the direction correctly.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
STRONG BUY
19 indicators
OscillatorsSTRONG BUY
3 buy · 4 neutral · 0 sell
Moving averagesSTRONG BUY
12 buy · 0 neutral · 0 sell
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 51.90 | NEUTRAL |
| Stochastic %K (14) | 66.16 | NEUTRAL |
| CCI (20) | 28.59 | NEUTRAL |
| Williams %R (14) | -33.84 | NEUTRAL |
| MACD (12,26,9) | 0.52 | BUY |
| ROC (10) | 0.60 | BUY |
| Momentum (10) | 1.25 | BUY |
| EMA (10) | 207.16 | BUY |
| SMA (10) | 206.03 | BUY |
| EMA (20) | 206.56 | BUY |
| SMA (20) | 206.26 | BUY |
| EMA (30) | 206.15 | BUY |
| SMA (30) | 206.31 | BUY |
| EMA (50) | 204.25 | BUY |
| SMA (50) | 207.60 | BUY |
| EMA (100) | 197.60 | BUY |
| SMA (100) | 196.63 | BUY |
| EMA (200) | 186.77 | BUY |
| SMA (200) | 183.64 | BUY |
About iShares Biotechnology ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
Background via Yahoo Finance — informational, not part of the verdict.
Grade verdict
No real edge — avoid
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BULLISH | 42 |
| ⏰ 4H | BULLISH | 37 |
| 🕐 1H | RANGING | 98 |
| ⏱ 15-Min | RANGING | 130 |
| ⏲ 5-Min | BULLISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
+0.6%
Rate of change (10d)
3.8×
Volume vs its 20-day average
0.20
MACD (no fresh cross)
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is a fund screened on its name?
No. HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A fund marketed as Islamic still gets the same look-through as any other.
What does unrated weight mean?
It is the share of the fund whose holdings HTR cannot cover far enough to rate. It is reported as unrated rather than counted as compliant, because a holding nobody screened should not look like one that passed.
Does the issuer's board make it compliant?
It matters, and it is noted, but it does not replace the look-through. The board's judgement and the holdings screen are shown separately so you can see when they agree and when they do not.
How often is this re-screened?
When the fund files new holdings, and on a rolling basis besides. The date on the verdict above is the last time this fund was actually recomputed.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-10-20 · Asset managers net 901377 (-14458)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.